| | 
Part, Chapter, Paragraph
501 III, 10. 2. 1 | among women.~ ~Figure 10.2.1.7.3. Prevalence of overweight
502 III, 10. 2. 1 | adolescents (Figure 10.2.1.7.4). For example, in England (
503 III, 10. 2. 1 | 2006).~ ~Figure 10.2.1.7.4. Trends of overweight
504 III, 10. 2. 1 | risen rapidly: more than 0.7 and more than 1.0 percentage
505 III, 10. 2. 1 | 2003), Denmark (0.9 and 0.7 pp/y, respectively, from
506 III, 10. 2. 1 | accounted for an additional 3.7% of DALYs lost, while more
507 III, 10. 2. 1 | 10.2.1.7.4. Risk factors~ ~The dietary
508 III, 10. 2. 1 | reported in table 10.2.1.7.1 whereas the gross human
509 III, 10. 2. 1 | reported in tables 10.2.1.7.2 to 10.2.1.7.5, respectively.
510 III, 10. 2. 1 | tables 10.2.1.7.2 to 10.2.1.7.5, respectively. Figure
511 III, 10. 2. 1 | respectively. Figure 10.2.1.7.5 shows the gross human
512 III, 10. 2. 1 | reported in Figure 10.2.1.7.6.~ ~Figure 10.2.1.7.5.
513 III, 10. 2. 1 | 2.1.7.6.~ ~Figure 10.2.1.7.5. Gross human apparent
514 III, 10. 2. 1 | 1 000 t)~ ~Table 10.2.1.7.1. Gross human apparent
515 III, 10. 2. 1 | 1 000 t)~ ~Table 10.2.1.7.2. Gross human apparent
516 III, 10. 2. 1 | meat, 2003~ ~Table 10.2.1.7.3. Gross human apparent
517 III, 10. 2. 1 | 1 000 t)~ ~Table 10.2.1.7.4. Gross human apparent
518 III, 10. 2. 1 | 1 000 t)~ ~Figure 10.2.1.7.5. Trends in gross human
519 III, 10. 2. 1 | 1995=100)~ ~Figure 10.2.1.7.6. Average annual growth
520 III, 10. 2. 1 | reported in Table 10.2.1.7.5.~ ~Table 10.2.1.7.5. DAFNE
521 III, 10. 2. 1 | 2.1.7.5.~ ~Table 10.2.1.7.5. DAFNE average consumption
522 III, 10. 2. 1 | FAO goals (table 10.2.1.7.7), there is little disagreement
523 III, 10. 2. 1 | FAO goals (table 10.2.1.7.7), there is little disagreement
524 III, 10. 2. 1 | products.~ ~Table 10.2.1.7.6. Comparisons between European
525 III, 10. 2. 1 | 10.2.1.7.5. Control tools and policies~ ~
526 III, 10. 2. 1 | 10.2.1.7.6. Risk reduction strategies~ ~
527 III, 10. 2. 1 | are different, and only 7 are the same (i. e.: eat
528 III, 10. 2. 1 | scientific data (Figure 10.2.1.7.7).~ ~Figure 10.2.1.7.7.
529 III, 10. 2. 1 | scientific data (Figure 10.2.1.7.7).~ ~Figure 10.2.1.7.7. FBDG
530 III, 10. 2. 1 | 1.7.7).~ ~Figure 10.2.1.7.7. FBDG for different population
531 III, 10. 2. 1 | 7.7).~ ~Figure 10.2.1.7.7. FBDG for different population
532 III, 10. 2. 1 | 10.2.1.7.7. Future developments~ ~
533 III, 10. 2. 1 | 10.2.1.7.7. Future developments~ ~In
534 III, 10. 2. 1 | 10.2.1.7.8. References~ ~Overweight
535 III, 10. 2. 1 | Portugal. Obesity Reviews 7:233-237.~ ~Dolman R, Kingdon
536 III, 10. 2. 1 | overweight and obesity in 7-9-year-old Portuguese children:
537 III, 10. 2. 1 | 2002): Body mass index in 7-9-y-old French children:
538 III, 10. 2. 4 | genetic disorders (see Chapter 7 on Rare Diseases). These
539 III, 10. 2. 4 | doi:10.1038/nrg2360: 2-7.~ ~Roberts, R, Sullivan
540 III, 10. 2. 4 | Consortium. Lancet Oncol, 7(1):27-38.~ ~Schulte in den
541 III, 10. 3. 1 | those during the night (23-7 hours) with 10 dB(A).~MRI~
542 III, 10. 4. 1 | databases/airbase/, accessed 7 March 2007).~ ~European
543 III, 10. 4. 2 | substances used in animal feed; (7) genetically modified organisms; (
544 III, 10. 4. 2(28)| 79/700/EEC (OJ L 187, 16.7.2002, p 30)~
545 III, 10. 4. 2(30)| OJ 121, 29.7.1964, p.1977~
546 III, 10. 4. 2 | per 100 000~Increasing (7.8% in 2005)~Poultry meat
547 III, 10. 4. 2 | cases in 2005 increased by 7.8% compared to the previous
548 III, 10. 4. 2 | mixing, from an average of 7 products per crop, to an
549 III, 10. 4. 2(35)| and on cereals (OJ L 221, 7.8.1986, p 37).~
550 III, 10. 4. 2(36)| animal origin (OJ L 221, 7.8.1986, p 43).~
551 III, 10. 4. 2 | a rough estimation about 7.5 millions of individual
552 III, 10. 4. 2 | values for nitrate (0-3.7 mg/kg b.w) and nitrite (
553 III, 10. 4. 2 | genetically modified organisms (7).~ ~GMOs and food products
554 III, 10. 4. 2 | Member States.~ ~Table 10.4.2.7. Food safety competent authorities
555 III, 10. 4. 2 | Environ Saf Vol. 63: 100-7~ ~RIVM (2006):Our Food,
556 III, 10. 4. 3 | were caused by protozoa (3.7% of cases of illness), two
557 III, 10. 4. 3 | Directive, Directive 2006/7/EC of the European parliament
558 III, 10. 4. 4 | is involved (see Figure 7.23), the importance of consumer
559 III, 10. 4. 4 | enforced (see also Chapter 7). To facilitate this, it
560 III, 10. 4. 4 | see also Chapter 7).~ ~ ~
561 III, 10. 4. 5 | Bathing Water Directive (2006/7/EC) introduces a higher
562 III, 10. 4. 5 | Directive, Directive 2006/7/EC of the European parliament
563 III, 10. 4. 5 | country~ ~Figure 10.4.5.2.7. Overview of contaminants
564 III, 10. 4. 5 | Europe (Figure 10.4.5.2.7). These estimates are based
565 III, 10. 4. 5 | related to exposure to 2,3,7,8-TCDD and related compounds)
566 III, 10. 5. 1 | 10.5.1.7. Control tools and policies~ ~
567 III, 10. 5. 2 | population.~ ~Figure 10.5.2.7. Life expectancy by gender
568 III, 10. 5. 2 | 8 years in urban and 75.7 years in rural settings).~
569 III, 10. 5. 2 | than in rural settings (11.7%) (Roel et al., 2005).~ ~
570 III, 10. 5. 2 | Ireland. BMC Public Health, 7:123.~[http://www.biomedcentral.
571 III, 10. 5. 2 | biomedcentral.com/1471-2458/7/123] (accessed on 19 September
572 III, 10. 5. 2 | 10.5.2.7. Acronyms~ ~BMA~British
573 III, 10. 5. 3 | up to 2.8 billion Euro in 7 European countries43. However,
574 III, 10. 5. 3 | people varied between 0.7 million Euro for Austria
575 III, 10. 5. 3 | accidents see also Chapter 7.~ ~Table 10.5.3.5. Incidence
576 III, 10. 5. 3 | economic sectors. Table 10.5.3.7 points to especially accident
577 III, 10. 5. 3 | 1994 to 2004~ ~Table 10.5.3.7. Standardised incidence
578 III, 10. 5. 3 | reached 56.3% in the EU25 (0.7 points below the Stockholm
579 III, 10. 5. 3 | duration (19.5% in Portugal, 25.7% in Poland, 33.3% in Spain).~·
580 III, 10. 5. 3 | people aged 55-64).~· 8.7 million were in long term
581 III, 10. 5. 3 | 10.5.3.7. Acronyms~ ~ENWHP~European
582 III, 10. 6. 1 | collection wave in 2006-7.~ ~
583 III, 10. 6. 1 | Depression. Health Rep 7:11-22.~ ~Börsch-Supan A,
584 III, 10. 6. 1 | Intern Med 167(18):1951-7.~ ~Ganster DC, Victor B (
585 III, 10. 6. 1 | 10.6.1.7. Acronyms~ ~HBSC~Health
586 III, 10. 6. 2 | actively promotes good health~7. Effective protection against
587 III, 10. 6. 2 | 10.6.2.7. Acronyms~ ~CSDH Commission
588 III, 10. 6. 3 | homicides, are quoted in Chapter 7.~ ~ ~
589 III, 10. 6. 3 | been carried out in Chapter 7 (See figure 7.17).~ ~Contact
590 III, 10. 6. 3 | in Chapter 7 (See figure 7.17).~ ~Contact crimes: The
591 III, 10. 6. 3 | Netherlands (1.4%). On average, 1.7% of women reported a victimisation.
592 IV, 11. 1. 5 | hospitalization in the US, where 2-7% of hospitalized patients
593 IV, 11. 1. 6 | services, not exceeding 7% of annual capitation).~
594 IV, 11. 2. 1 | is minimal (11.4. versus 7.9), partly owing to the
595 IV, 11. 2. 1 | 4%), Austria and Cyprus (7.5%). Despite the general
596 IV, 11. 2. 2 | Netherlands (from 3.5% to 4.7%) (OECD Health data 2007).
597 IV, 11. 2. 2 | prevention accounting for about 0.7% in Italy, to 4.7% in the
598 IV, 11. 2. 2 | about 0.7% in Italy, to 4.7% in the Netherlands and
599 IV, 11. 3. 2 | Indeed, as shown in Table 11.7, the growth in spending
600 IV, 11. 3. 2 | Czech Republic (Table 11.7).~ ~Additionally, while
601 IV, 11. 3. 2 | Turkey (HFA 2007).~ ~Table 11.7. Spending on pharmaceuticals
602 IV, 11. 4 | decision-making. Figure 11.7 depicts how HTA projects
603 IV, 11. 4 | specific policies.~ ~Figure 11.7. Relations between research
604 IV, 11. 5. 5 | fundamental research.~- 7 member states partners :
605 IV, 11. 5. 6 | 2006 and 2007.~ ~Annex 11.7.1. List of recommendations
606 IV, 11. 5. 7 | 11.5.7. Future developments~ ~The
607 IV, 11. 6. 1 | had increased to nearly 7%. Today, it has climbed
608 IV, 11. 6. 2 | the rise in spending from 7.3% to 8.3% GDP in a four-year
609 IV, 11. 6. 2 | payments sometimes, while 5.7% made payments on almost
610 IV, 11. 6. 3 | to opt out. However, only 7% choose to be fully covered
611 IV, 11. 6. 4 | Czech Republic~General fund + 7 sector/enterprise funds*~
612 IV, 11. 6. 4 | Health Insurance Fund with 7 regional departments~Regional
613 IV, 11. 6. 4 | Central Ministry of Health~7 autonomous communities~Cross-boundary
614 IV, 11. 6. 5 | 11.7. References~ ~Altman S,
615 IV, 11. 6. 5 | Netherlands." Euro Health 12(2): 7-9.~ ~Belli P (2003): Formal
616 IV, 11. 6. 5 | J Clin Oncol 22: 2000-7.~ ~Busse R, Schreyogg J
617 IV, 11. 6. 5 | Medical Care Review 37(7): 653-98.~ ~Dovey SM, Meyers
618 IV, 11. 6. 5 | Europe." Health Economics 13(7): 629-647.~ ~van Doorslaer
619 IV, 12. 2 | on health. Over the last 7 years, EU public health
620 IV, 12. 2 | principle (see Section 12.7.), and is likely to make
621 IV, 12. 2 | measures and programmes.~On 7 February 2008 WHO released
622 IV, 12. 3 | social agenda fall into 7 priority sectors:~· Infancy
623 IV, 12. 4 | policy makers (Table 12.7). Working as technical secretariats
624 IV, 12. 4 | established in 2006.~Table 12.7. Community agencies directly
625 IV, 12. 7 | 12.7. Health in all policies~ ~
626 IV, 12. 10 | policies for men and women by:~7. reconciling the demands
627 IV, 12. 10 | snuff use~ high~ Law 31/7/2003 aiming to limit the
628 IV, 12. 10 | Recreational water – Directive 2006/7/EC of the European Parliament
629 IV, 12. 10 | in blue colour jobs and 7) improving systems for monitoring~
630 IV, 12. 10 | health-promoting health service~7. Effective protection against
631 IV, 13.Acr | FP7~Framework Programme 7~LMI~Lead Market” Initiative~
632 IV, 13. 2. 2 | 1st and accounts for 13.7% of YLDs, followed by alcohol
633 IV, 13. 2. 2 | accounted for an additional 3.7% of DALYs lost, while more
634 IV, 13. 2. 3 | attributable to hypertension, 7.4% and 7.4% to high cholesterol
635 IV, 13. 2. 3 | to hypertension, 7.4% and 7.4% to high cholesterol and
636 IV, 13. 2. 3 | selected conditions. Table 13.7 presents a comparison of
637 IV, 13. 2. 3 | and depression. Table 13.7 also shows that the demonstrable
638 IV, 13. 7 | 13.7. Innovation~ ~Never before
639 IV, 13. 7. 1 | 13.7.1. “Innovation Cluster”
640 IV, 13. 7. 2 | 13.7.2. “Lead Market” initiative~ ~
641 IV, 13. 7. 2 | producing high-tech goods (7% of total workforce compared
642 IV, 13. 7. 3 | 13.7.3. Research~ ~One of the
643 IV, 13. 7. 3 | the ERC is funded with EUR 7.5 billion over 7 years,
644 IV, 13. 7. 3 | with EUR 7.5 billion over 7 years, it has already become
645 IV, 13. 7. 4 | 13.7.4. Ethical issues~ ~Ethical
646 IV, 13. 7. 5 | 13.7.5. Personal data protection
|
|
| |
